Extended Data Fig. 2: Relationship between protein levels and reaching target testosterone in the SPIRO-GAHT group.
From: Plasma proteome adaptations during feminizing gender-affirming hormone therapy
A. Volcano plot of significant proteins in the SPIRO sub-groups that reach target testosterone (left panel, n = 9) and do not reach target testosterone (right panel, n = 11). The y-axis represents -the log10 unadjusted p-value, and the x-axis represents the NPX log2 fold change (6 M – 0 M). The dashed y-intercepts indicate a p-value of <0.05. B. Dot plot showing change in protein rank (log10 scale, y-axis) between ‘reach’ and ‘do not reach’ testosterone groups for the top 20 proteins associated with CPA-GAHT (x-axis). Red dots: testis-produced proteins. Black arrow indicates weaker significance in ‘do not reach group’, red arrow indicates stronger significance in ‘do not reach group’ relative to ‘reach testostorone’ group. C. Boxplot for SPINT3 NPX level at baseline and 6 months post CPA-GAHT and SPIRO-GAHT (n = 20 participant in each boxplot). Boxplot of SPINT3 levels in SPIRO group by target testosterone (n = 20 for 0 m, n = 11 for 6 m not reached target, n = 9 for 6 m reached target). Correlation plot of testosterone concentration and SPINT3 NPX values. Grey shaded error band represents the 95% confidence interval of the fit. Boxplots show the median (centre), 25th–75th percentiles (bounds), and whiskers extending to minima and maxima within 1.5×IQR; outliers are plotted individually.
